📇 Rhumatologue · LA ROCHE SUR YON CEDEX 9 · (85) · Salarié

M Yves-Marie PLUCHON

Pourquoi vous devez consulter ce praticien

2 raisons identifiées

Praticien-chercheur
7 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
97.1 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 LA ROCHE SUR YON CEDEX 9 (85)SalariéRPPS 10002570686

Publications actives

8 publications sur 5 ans

📊 Reconnaissance scientifique : 3/100📝 10 articles publiés🇫🇷 Publications académiques françaises (3)

✨ Génération du profil synthétique IA en cours…

Activité de recherche & publications

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Peripheral Neuropathic Pain Following Breast Cancer: Effectiveness and Tolerability of High-Concentration Capsaicin Patch

Journal of pain research · 2022

📚 17 citations🎯 RCR 2.13Top 25% NIH🔓 Open Access📄 PDF gratuit ↗

Ketamine in chronic pain: A Delphi survey

European journal of pain (London, England) · 2022

📚 13 citations🎯 RCR 1.92🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

AbstractBackgroundThere is no recommendation in Europe for the use of ketamine in patients with chronic pain. The heterogeneity of practice highlights the need to seek the advice of experts in order to establish a national consensus. This Delphi survey aimed to reach a national consensus on the use of ketamine in chronic pain in Pain clinics.MethodsA collaborative four‐round internet‐based questionnaire was used. It was created after literature search on ketamine administration in chronic pain and included about 96 items. It discussed utility and advantages, adverse events and deleterious aspects, methods of administration, concomitant treatments and assessment of results.ResultsTwenty‐eight experts completed all rounds of the survey with a total of 81.3% items reaching a consensual answer. Neuropathic pain represents the first indication to use ketamine, followed, with a good to moderate utility, by other situations (fibromyalgia, complex regional pain syndrome, central neuropathic pain, peripheral neuropathic pain, nociceptive pain, sensitization, opioid withdrawal, palliative care, depression). Experts agreed on the rare occurrence of adverse events. Concerning routes of administration, intravenous infusion with doses of 0.5–0.9 mg/kg/d for 4 days of treatment is preferred. Place of care is hospital, as in‐ or out‐patient, with a quarterly administration of ketamine. Finally, ketamine effectiveness is assessed 1 month after infusion, and experts encourage combination with non‐pharmacological treatment.ConclusionsThis Delphi survey established a consensus of pain specialists on the use of ketamine in refractory chronic pain, thus providing a basis for future comparative trials.SignificanceThis Delphi survey in chronic pain reached agreement on four main aspects: (1) Priority to treat neuropathic pain with evaluation of effectiveness at 1 month; (2) No deleterious effects in the majority of listed diseases/situations with the absence or <3% of suggested adverse events; (3) 0.5–0.9 mg/kg/d IV infusion; (4) Combination with non‐pharmacological treatment.

Intrathecal cervical analgesia for cancer pain: a 12-year follow-up study in a comprehensive cancer center

Regional anesthesia and pain medicine · 2024

📚 6 citations🎯 RCR 3.19Top 15% NIH

Lire l'abstract Crossref ↓

Background Intrathecal analgesia plays a key role for patients suffering refractory cancer pain. Nevertheless, intrathecal drug delivery systems (IDDS), requiring a cervical catheter tip implantation, have been poorly described in medical literature. Aims A monocentric retrospective follow-up study was designed to evaluate results of cervical IDDS for cancer pain. Patients and methods From January 2010 to December 2022, all intrathecal-treated patients were prescribed a combined intrathecal analgesics regimen through a catheter placed in the cervical vertebral canal. Post-implant assessment of pain was determined using a numeric rating scale (NRS). Patients were followed via day-hospital visits and telephone calls at least monthly. Pain scores were compared using the Wilcoxon’s signed rank test. Results Ninety-eight patients were included in this study; all received intrathecal treatments. Implanted patients suffered from severe pain (mean presurgical maximum numerical rating score 8.02±0.24 despite a mean 562.56±127.72 mg of oral morphine equivalent daily dose). Mean survival time after intrathecal treatment start was 208.48±67 days. Intrathecal drug delivery systems provided pain relief compared with initial pain score with a significant statistical difference after 1 week, 1 month, 2 and 3 months (p<0.01). A 50% reduction in initial pain level was achieved in 93% of cases during the first week of intrathecal implant. Conclusions Results suggest that long-term intrathecal treatment using a multidrug regimen for cancer-related pain through cervical intrathecal catheters was suitable and safe in our study population. We demonstrated a clinically and statistically significant pain reduction in patients using mainly a percutaneous lumbar approach.

Cookies & analyse de trafic

M Yves-Marie PLUCHON

Pourquoi vous devez consulter ce praticien

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (7) — classées par pathologie

Essai clinique4

Transversal2

Activité physique / Rééducation1

Qualité de vie / PROMs1

Vraie vie / RWE1

Partager cette fiche